Cargando…
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy
Tumor immune escape has emerged as the most significant barrier to cancer therapy. A thorough understanding of tumor immune escape therapy mechanisms is critical for further improving clinical treatment strategies. Currently, research indicates that combining several immunotherapies can boost antitu...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989557/ https://www.ncbi.nlm.nih.gov/pubmed/35401745 http://dx.doi.org/10.1155/2022/8901326 |
_version_ | 1784683202008317952 |
---|---|
author | Aktar, Nasrin Yueting, Chen Abbas, Muhammad Zafar, Hajra Paiva-Santos, Ana Cláudia Zhang, Qin Chen, Tingting Ahmed, Moudud Raza, Faisal Zhou, Xiaohui |
author_facet | Aktar, Nasrin Yueting, Chen Abbas, Muhammad Zafar, Hajra Paiva-Santos, Ana Cláudia Zhang, Qin Chen, Tingting Ahmed, Moudud Raza, Faisal Zhou, Xiaohui |
author_sort | Aktar, Nasrin |
collection | PubMed |
description | Tumor immune escape has emerged as the most significant barrier to cancer therapy. A thorough understanding of tumor immune escape therapy mechanisms is critical for further improving clinical treatment strategies. Currently, research indicates that combining several immunotherapies can boost antitumor efficacy and encourage T cells to play a more active part in the immune assault. To generate a more substantial therapeutic impact, it can establish an ideal tumor microenvironment (TME), encourage T cells to play a role, prevent T cell immune function reversal, and minimize tumor immune tolerance. In this review, we will examine the mechanisms of tumor immune escape and the limits of tumor immune escape therapy, focusing on the current development of immunotherapy based on tumor immune escape mechanisms. Individualized tumor treatment is becoming increasingly apparent as future treatment strategies. In addition, we forecast the future research direction of cancer and the clinical approach for cancer immunotherapy. It will serve as a better reference for researchers working in cancer therapy research. |
format | Online Article Text |
id | pubmed-8989557 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-89895572022-04-08 Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy Aktar, Nasrin Yueting, Chen Abbas, Muhammad Zafar, Hajra Paiva-Santos, Ana Cláudia Zhang, Qin Chen, Tingting Ahmed, Moudud Raza, Faisal Zhou, Xiaohui J Oncol Review Article Tumor immune escape has emerged as the most significant barrier to cancer therapy. A thorough understanding of tumor immune escape therapy mechanisms is critical for further improving clinical treatment strategies. Currently, research indicates that combining several immunotherapies can boost antitumor efficacy and encourage T cells to play a more active part in the immune assault. To generate a more substantial therapeutic impact, it can establish an ideal tumor microenvironment (TME), encourage T cells to play a role, prevent T cell immune function reversal, and minimize tumor immune tolerance. In this review, we will examine the mechanisms of tumor immune escape and the limits of tumor immune escape therapy, focusing on the current development of immunotherapy based on tumor immune escape mechanisms. Individualized tumor treatment is becoming increasingly apparent as future treatment strategies. In addition, we forecast the future research direction of cancer and the clinical approach for cancer immunotherapy. It will serve as a better reference for researchers working in cancer therapy research. Hindawi 2022-03-31 /pmc/articles/PMC8989557/ /pubmed/35401745 http://dx.doi.org/10.1155/2022/8901326 Text en Copyright © 2022 Nasrin Aktar et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Aktar, Nasrin Yueting, Chen Abbas, Muhammad Zafar, Hajra Paiva-Santos, Ana Cláudia Zhang, Qin Chen, Tingting Ahmed, Moudud Raza, Faisal Zhou, Xiaohui Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title_full | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title_fullStr | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title_full_unstemmed | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title_short | Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy |
title_sort | understanding of immune escape mechanisms and advances in cancer immunotherapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8989557/ https://www.ncbi.nlm.nih.gov/pubmed/35401745 http://dx.doi.org/10.1155/2022/8901326 |
work_keys_str_mv | AT aktarnasrin understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT yuetingchen understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT abbasmuhammad understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT zafarhajra understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT paivasantosanaclaudia understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT zhangqin understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT chentingting understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT ahmedmoudud understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT razafaisal understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy AT zhouxiaohui understandingofimmuneescapemechanismsandadvancesincancerimmunotherapy |